Sign In
Buy OKYO
$1.55
+0.0700 (+4.73%)
At Close: Jul 24, 2026
OKYO Pharma Announces Chairman and Founder Acquires Shares
08:30am, Friday, 21'st Nov 2025
LONDON and NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corne
OKYO Pharma to Present at OIS XV in San Diego
08:30am, Tuesday, 18'th Nov 2025
LONDON and NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corne
OKYO Pharma Announces Chairman and Founder Acquires Shares
08:30am, Thursday, 16'th Oct 2025
LONDON and NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corne
OKYO Pharma reports company stock purchase by executive chair
04:49am, Thursday, 16'th Oct 2025
OKYO Pharma Ltd (NASDAQ:OKYO) said it has been informed that Panetta Partners Limited, an entity in which the company’s executive chairman Gabriele Cerrone...
OKYO Pharma maps out registration path with 100-patient trial of Urcosimod for neuropathic corneal pain
08:47am, Monday, 22'nd Sep 2025
OKYO Pharma Ltd (NASDAQ:OKYO) plans to run a 100-patient, multi-centre study of its eye-drop candidate Urcosimod in neuropathic corneal pain, laying out a path it hopes can lead to US approval in a c
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
08:30am, Monday, 22'nd Sep 2025
LONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corne
OKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMI
11:51am, Saturday, 19'th Jul 2025
OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the recently announced topline data from the company's Phase 2 trial evaluating urcosimod in patients with neuropathic corneal
OKYO Pharma secures $1.9M in non-dilutive funding to advance clinical development of NCP therapy
09:31am, Thursday, 17'th Jul 2025
OKYO Pharma Ltd (NASDAQ:OKYO) announced it has secured $1.9 million in non-dilutive funding to support the development of urcosimod, its lead drug candidate for neuropathic corneal pain (NCP). NCP is
OKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal pain
09:42am, Wednesday, 16'th Jul 2025
OKYO Pharma Ltd (NASDAQ:OKYO) on Wednesday reported promising top-line results from a Phase 2 trial of its investigational drug urcosimod for neuropathic corneal pain (NCP), with 75% of patients showi
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
09:21am, Wednesday, 16'th Jul 2025
LONDON and NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic cornea
OKYO Pharma poised for breakout as Phase 2 trial nears results: analysts
02:00pm, Wednesday, 11'th Jun 2025
Shares of OKYO Pharma Ltd (NASDAQ:OKYO) have nearly doubled since the start of the year, fueled by a string of clinical and regulatory milestones that may pave the way for a transformative treatment
Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited
10:05am, Wednesday, 11'th Jun 2025
Raising Price Target Due to Fundamental Drivers BALTIMORE, MD / ACCESS Newswire / June 11, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap se
OKYO Pharma CEO to present drug research for debilitating eye pain at Boston summit
09:35am, Monday, 19'th May 2025
OKYO Pharma Ltd (NASDAQ:OKYO) shares could see renewed attention this week as the company's chief executive, Gary Jacob, is set to present findings on its lead drug candidate at a biotech conference i
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
07:00am, Monday, 19'th May 2025
LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic co
OKYO moves toward FDA talks after eye drug trial – ICYMI
05:18pm, Friday, 02'nd May 2025
OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week announced the early termination of its Phase 2 trial evaluating urcosimod (formerly OK-101) for neuropathic corneal pain. The company said the 48-patien
